243 related articles for article (PubMed ID: 32122592)
1. Efficacy in pigs of a new inactivated vaccine combining porcine circovirus type 2 and Mycoplasma hyorhinis.
Wei YW; Zhu HZ; Huang LP; Xia DL; Wu HL; Bian HQ; Feng L; Liu CM
Vet Microbiol; 2020 Mar; 242():108588. PubMed ID: 32122592
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of a new bivalent vaccine of porcine circovirus type 2 and Mycoplasma hyopneumoniae (Fostera™ PCV MH) under experimental conditions.
Park C; Jeong J; Choi K; Chae C
Vaccine; 2016 Jan; 34(2):270-275. PubMed ID: 26626212
[TBL] [Abstract][Full Text] [Related]
3. Efficacy comparison of commercial porcine circovirus type 2 (PCV2) and
Yang S; Park SJ; Oh T; Cho H; Chae C
Can J Vet Res; 2020 Oct; 84(4):272-282. PubMed ID: 33012976
[TBL] [Abstract][Full Text] [Related]
4. A Porcine circovirus type 2b (PCV2b)-based experimental vaccine is effective in the PCV2b-Mycoplasma hyopneumoniae coinfection pig model.
Opriessnig T; Castro AMMG; Karuppanan AK; Gauger PC; Halbur PG; Matzinger SR; Meng XJ
Vaccine; 2019 Oct; 37(44):6688-6695. PubMed ID: 31537445
[TBL] [Abstract][Full Text] [Related]
5. An experimental live chimeric porcine circovirus 1-2a vaccine decreases porcine circovirus 2b viremia when administered intramuscularly or orally in a porcine circovirus 2b and porcine reproductive and respiratory syndrome virus dual-challenge model.
Opriessnig T; Gomes-Neto JC; Hemann M; Shen HG; Beach NM; Huang Y; Halbur PG; Meng XJ
Microbiol Immunol; 2011 Dec; 55(12):863-73. PubMed ID: 21951266
[TBL] [Abstract][Full Text] [Related]
6. Synergistic pathogenicity in sequential coinfection with Mycoplasma hyorhinis and porcine circovirus type 2.
Chen D; Wei Y; Huang L; Wang Y; Sun J; Du W; Wu H; Liu C
Vet Microbiol; 2016; 182():123-30. PubMed ID: 26711038
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the efficacy of a trivalent vaccine mixture against a triple challenge with Mycoplasma hyopneumoniae, PCV2, and PRRSV and the efficacy comparison of the respective monovalent vaccines against a single challenge.
Oh T; Park KH; Yang S; Jeong J; Kang I; Park C; Chae C
BMC Vet Res; 2019 Oct; 15(1):342. PubMed ID: 31619295
[TBL] [Abstract][Full Text] [Related]
8. A new single-dose bivalent vaccine of porcine circovirus type 2 and Mycoplasma hyopneumoniae elicits protective immunity and improves growth performance under field conditions.
Jeong J; Park C; Choi K; Chae C
Vet Microbiol; 2016 Jan; 182():178-86. PubMed ID: 26711046
[TBL] [Abstract][Full Text] [Related]
9. A PCV2 vaccine based on genotype 2b is more effective than a 2a-based vaccine to protect against PCV2b or combined PCV2a/2b viremia in pigs with concurrent PCV2, PRRSV and PPV infection.
Opriessnig T; O'Neill K; Gerber PF; de Castro AM; Gimenéz-Lirola LG; Beach NM; Zhou L; Meng XJ; Wang C; Halbur PG
Vaccine; 2013 Jan; 31(3):487-94. PubMed ID: 23174198
[TBL] [Abstract][Full Text] [Related]
10. A commercial porcine circovirus (PCV) type 2a-based vaccine reduces PCV2d viremia and shedding and prevents PCV2d transmission to naïve pigs under experimental conditions.
Opriessnig T; Xiao CT; Halbur PG; Gerber PF; Matzinger SR; Meng XJ
Vaccine; 2017 Jan; 35(2):248-254. PubMed ID: 27919634
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with a Porcine Reproductive and Respiratory Syndrome (PRRS) Modified Live Virus Vaccine Followed by Challenge with PRRS Virus and Porcine Circovirus Type 2 (PCV2) Protects against PRRS but Enhances PCV2 Replication and Pathogenesis Compared to Results for Nonvaccinated Cochallenged Controls.
Niederwerder MC; Bawa B; Serão NV; Trible BR; Kerrigan MA; Lunney JK; Dekkers JC; Rowland RR
Clin Vaccine Immunol; 2015 Dec; 22(12):1244-54. PubMed ID: 26446422
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy of experimental inactivated and live-attenuated chimeric porcine circovirus (PCV) 1-2b vaccines derived from PCV1 and PCV2b isolates originated in China.
Li J; Yu T; Wang X; Zhou J; Gao R; Zhang F; Gao X; Gao S; Liu X
Virol J; 2015 Jul; 12():113. PubMed ID: 26220290
[TBL] [Abstract][Full Text] [Related]
13. A commercial PCV2a-based vaccine is effective in protection from experimental challenge of PCV2 mutant with two amino acids elongation in capsid protein.
Guo LJ; Fu YJ; Huang LP; Wang YP; Wei YW; Wu HL; Liu CM
Vaccine; 2015 Jul; 33(31):3752-7. PubMed ID: 26051516
[TBL] [Abstract][Full Text] [Related]
14. A comparative efficacy test of 1
Do DT; Tran KDV; Quach AT; Lee D; Chang FC; Wu CP; Tat TN; Chae C
Can J Vet Res; 2021 Apr; 85(2):93-100. PubMed ID: 33883815
[TBL] [Abstract][Full Text] [Related]
15. Effect of porcine circovirus type 2 (PCV2) vaccination on porcine reproductive and respiratory syndrome virus (PRRSV) and PCV2 coinfection.
Opriessnig T; Madson DM; Prickett JR; Kuhar D; Lunney JK; Elsener J; Halbur PG
Vet Microbiol; 2008 Sep; 131(1-2):103-14. PubMed ID: 18430525
[TBL] [Abstract][Full Text] [Related]
16. Duration of immunity for an inactivated Mycoplasma hyorhinis vaccine in pigs.
Martinson B; Zoghby W; Barrett K; Bryson L; Kroll J
Vet Microbiol; 2019 Mar; 230():273-277. PubMed ID: 30827400
[TBL] [Abstract][Full Text] [Related]
17. A candidate inactivated chimeric vaccine PCV1-2 constructed based on PCV1 and PCV2 isolates originating in China and its evaluation in conventional pigs in regard to protective efficacy against PCV2 infection.
Xujie L; Xiaobo W; Yi S; Jing F; Song G; Xiufan L
Microbiol Immunol; 2011 Apr; 55(4):254-66. PubMed ID: 21244470
[TBL] [Abstract][Full Text] [Related]
18. Comparison of sow and/or piglet vaccination of 3 commercial porcine circovirus type 2 (PCV2) single-dose vaccines on pigs under experimental PCV2 challenge.
Oh Y; Seo HW; Park C; Chae C
Vet Microbiol; 2014 Aug; 172(3-4):371-80. PubMed ID: 24970364
[TBL] [Abstract][Full Text] [Related]
19. Experimental efficacy of a trivalent vaccine containing porcine circovirus types 2a/b (PCV2a/b) and Mycoplasma hyopneumoniae against PCV2d and M. hyopneumoniae challenges.
Yang S; Oh T; Park KH; Cho H; Suh J; Chae C
Vet Microbiol; 2021 Jul; 258():109100. PubMed ID: 33984792
[TBL] [Abstract][Full Text] [Related]
20. A commercial vaccine based on PCV2a and an experimental vaccine based on a variant mPCV2b are both effective in protecting pigs against challenge with a 2013 U.S. variant mPCV2b strain.
Opriessnig T; Gerber PF; Xiao CT; Mogler M; Halbur PG
Vaccine; 2014 Jan; 32(2):230-7. PubMed ID: 24269319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
